We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA has announced two major personnel changes, moving Janet Woodcock to oversee a new office and inserting John Dyer as deputy commissioner for operations and chief operating officer (COO) of the agency.
Schering-Plough's fourth quarter profits for 2006 rose 75 percent from the same time period in 2005, and its net income for the same period was $182 million, up from $104 million in the fourth quarter of 2005, the company announced.
The FTC is set to approve a plan proposed by Hospira to acquire Australia-based generic firm Mayne Pharma for $2 billion, as long as certain conditions are met, the agency has announced.
All "unanticipated problems" affecting participants in clinical trials sponsored or supported by HHS must be reported, a new guidance from the Office for Human Research Protections (OHRP) says.
The NIH is placing greater emphasis on bringing new researchers into the R&D pipeline and rewarding more productive labs to make the most of what is likely a flat budget in fiscal 2008, a high-ranking agency official says.
Novartis' fourth quarter net profit for 2006 rose 23 percent with strong showings from hypertension drug Diovan and leukemia drug Gleevec, the company announced.
Republican members of the House and Senate are proposing a federal commission to study entitlement spending, including Medicare and Medicaid, with an eye toward developing ways to lower the costs of these programs.
Bristol-Myers Squibb (BMS) reported a net loss from continuing operations of $134 million on sales of $4.2 billion in the fourth quarter of 2006, compared with net earnings of $499 million on sales of $5 billion for the same period in 2005.
The FDA warned WellSpring Pharmaceutical for a print advertisement the agency said was misleading and overstated the safety and effectiveness of its drug, including using inappropriate studies as supporting evidence.